Prognostic lncRNAs for stomach adenocarcinoma and drug sensitivity analysis
10.13699/j.cnki.1001-6821.2024.01.005
- VernacularTitle:胃腺癌预后非编码长链RNA及抗肿瘤药敏分析
- Author:
Yu-Mei HUANG
1
;
Jing HUANG
;
A-Zhen WU
Author Information
1. 厦门大学附属第一医院药剂科,福建厦门 361001
- Keywords:
stomach adenocarcinoma;
long non-coding RNAs;
drug sensitivity analysis;
prognosis
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(1):22-26
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the prognostic value of long non-coding RNAs(lncRNAs)as novel biomarkers for stomach adenocarcinoma(STAD).Methods RNA-seq transcriptome data and clinical details for STAD were downloaded from the The Cancer Genome Atlas(TCGA)database.Differentially expressed lncRNAs were identified by bioinformatics analysis.Survival analysis,independent prognostic analysis and receiver operating characteristic(ROC)curve were used to identify lncRNAs with independent prognostic value.Then,Gene ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)were used to evaluate the biological profiles of the co-expressed genes.Finally,oncoPredict R package was used to predict the drug sensitivity.Results A total of 1 583 differentially expressed lncRNAs were identified from STAD tumor tissues.A lncRNAs AP000695.1 with survival and independent prognostic value was screened.The area under 5-year survival ROCs was 0.836.AP000695.1 was co-expressed with 16 genes involved in tumor cell invasion,metastasis and diffusion.Finally,anti-tumor drug sensitivity prediction revealed that patients in the low expression group were more sensitive to anti-tumor drugs.Conclusion This study discovered a risk factor lncRNAs AP000695.1 with independent prognostic value,may provide insight for individualized antitumor therapy and prognosis prediction for STAD patients.
